Equipment to Support Prophylactic Antibacterial Vaccine Development

支持预防性抗菌疫苗开发的设备

• 批准号: 103264
• 金额: $ 6.05万
• 依托单位: ABSYNTH BIOLOGICS LIMITED
• 依托单位国家: 英国
• 项目类别: Centres
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103264
• 关键词: Equipment; Support; Prophylactic; Antibacterial; Vaccine

Absynth is developing vaccines to prevent bacterial infections to address the challenge of antimicrobial resistance (AMR). Vaccines are important as prevention of infections will directly reduce the need for antibiotics. Also such prophylactic vaccines have never been shown to induce resistance. Absynth’s R&D focuses on vaccines against the infectious bacteria Staphylococcus aureus and Clostridium difficile - important to public health because of the damage and death caused by these pathogens. Absynth is able to compete against the competition because it has a suite of novel protein vaccine antigens that differ from and potentially offer benefits over competitor products. Absynth is seeking a grant to purchase equipment costing £95,000, for use in its R&D programmes. Originally Absynth leased second-hand equipment but after three years key pieces of equipment are increasingly unreliable, impacting Absynth’s ability to carry out its work. The investment is good value for money for Absynth and the taxpayer as using the new equipment the company will advance the S. aureus vaccine to the stage where the partner it has already secured, will fund preclinical safety studies and clinical trials through to market.

Absynth正在开发预防细菌感染的疫苗，以应对抗菌素耐药性（AMR）的挑战。疫苗很重要，因为预防感染将直接减少对抗生素的需求。此外，这种预防性疫苗从未显示会引起耐药性。Absynth的研发重点是针对传染性细菌金黄色葡萄球菌和艰难梭菌的疫苗，这两种细菌对公共卫生很重要，因为这些病原体会造成损害和死亡。Absynth能够与竞争对手竞争，因为它拥有一套新的蛋白质疫苗抗原，与竞争对手的产品不同，而且可能比竞争对手的产品更有优势。Absynth正在寻求拨款，以购买价值9.5万英镑的设备，用于其研发项目。最初，Absynth租用的是二手设备，但三年后，关键设备变得越来越不可靠，影响了Absynth开展工作的能力。这笔投资对Absynth和纳税人来说都是物有所值的，因为使用新设备，公司将把金黄色葡萄球菌疫苗推进到它已经确定的合作伙伴的阶段，将资助临床前安全性研究和临床试验，并将其推向市场。